Logo image of CASI

CASI PHARMACEUTICALS INC (CASI) Stock Fundamental Analysis

NASDAQ:CASI - Nasdaq - KYG1933S1012 - Common Stock - Currency: USD

1.315  -0.02 (-1.13%)

Fundamental Rating

1

Overall CASI gets a fundamental rating of 1 out of 10. We evaluated CASI against 555 industry peers in the Biotechnology industry. CASI has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CASI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CASI has reported negative net income.
In the past 5 years CASI always reported negative net income.
In the past 5 years CASI always reported negative operating cash flow.
CASI Yearly Net Income VS EBIT VS OCF VS FCFCASI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

CASI has a worse Return On Assets (-99.16%) than 76.04% of its industry peers.
Industry RankSector Rank
ROA -99.16%
ROE N/A
ROIC N/A
ROA(3y)-50.53%
ROA(5y)-43.18%
ROE(3y)-774.83%
ROE(5y)-485.42%
ROIC(3y)N/A
ROIC(5y)N/A
CASI Yearly ROA, ROE, ROICCASI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

CASI has a better Gross Margin (56.62%) than 78.02% of its industry peers.
In the last couple of years the Gross Margin of CASI has grown nicely.
CASI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.45%
GM growth 5Y63.76%
CASI Yearly Profit, Operating, Gross MarginsCASI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

0

2. Health

2.1 Basic Checks

CASI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CASI has more shares outstanding
The number of shares outstanding for CASI has been increased compared to 5 years ago.
CASI has a worse debt/assets ratio than last year.
CASI Yearly Shares OutstandingCASI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
CASI Yearly Total Debt VS Total AssetsCASI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -26.41, we must say that CASI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CASI (-26.41) is worse than 89.19% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.41
ROIC/WACCN/A
WACC6.32%
CASI Yearly LT Debt VS Equity VS FCFCASI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.81 indicates that CASI may have some problems paying its short term obligations.
CASI has a Current ratio of 0.81. This is amonst the worse of the industry: CASI underperforms 89.91% of its industry peers.
CASI has a Quick Ratio of 0.81. This is a bad value and indicates that CASI is not financially healthy enough and could expect problems in meeting its short term obligations.
CASI has a worse Quick ratio (0.68) than 90.45% of its industry peers.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.68
CASI Yearly Current Assets VS Current LiabilitesCASI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

CASI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.09%.
The Revenue has grown by 8.39% in the past year. This is quite good.
CASI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 47.19% yearly.
EPS 1Y (TTM)-10.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.82%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y-1.84%
Revenue growth 5Y47.19%
Sales Q2Q%83.04%

3.2 Future

CASI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.15% yearly.
The Revenue is expected to decrease by -10.80% on average over the next years. This is quite bad
EPS Next Y19.14%
EPS Next 2Y25.47%
EPS Next 3Y16.43%
EPS Next 5Y21.15%
Revenue Next Year-5.03%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-10.8%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CASI Yearly Revenue VS EstimatesCASI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2019 2020 2021 2022 2023 2024 2025 2029 2030 2031 2032 20M 40M 60M
CASI Yearly EPS VS EstimatesCASI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CASI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CASI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CASI Price Earnings VS Forward Price EarningsCASI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CASI Per share dataCASI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

CASI's earnings are expected to grow with 16.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.47%
EPS Next 3Y16.43%

More info and screens

0

5. Dividend

5.1 Amount

CASI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CASI PHARMACEUTICALS INC

NASDAQ:CASI (7/2/2025, 3:08:19 PM)

1.315

-0.02 (-1.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-16 2025-05-16/bmo
Earnings (Next)08-14 2025-08-14
Inst Owners15.06%
Inst Owner ChangeN/A
Ins Owners20.4%
Ins Owner Change0%
Market Cap20.37M
Analysts82.86
Price Target4.08 (210.27%)
Short Float %0.17%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.05
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)38.69%
Min Revenue beat(2)0.29%
Max Revenue beat(2)77.09%
Revenue beat(4)3
Avg Revenue beat(4)33.24%
Min Revenue beat(4)-11.97%
Max Revenue beat(4)77.09%
Revenue beat(8)3
Avg Revenue beat(8)1.39%
Revenue beat(12)6
Avg Revenue beat(12)3.96%
Revenue beat(16)8
Avg Revenue beat(16)4.06%
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-59.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.65
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.51
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.03
BVpS-0.52
TBVpS-0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.16%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.62%
FCFM N/A
ROA(3y)-50.53%
ROA(5y)-43.18%
ROE(3y)-774.83%
ROE(5y)-485.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.45%
GM growth 5Y63.76%
F-ScoreN/A
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.68
Altman-Z -26.41
F-ScoreN/A
WACC6.32%
ROIC/WACCN/A
Cap/Depr(3y)100.64%
Cap/Depr(5y)428.5%
Cap/Sales(3y)6.82%
Cap/Sales(5y)39.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.82%
EPS Next Y19.14%
EPS Next 2Y25.47%
EPS Next 3Y16.43%
EPS Next 5Y21.15%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y-1.84%
Revenue growth 5Y47.19%
Sales Q2Q%83.04%
Revenue Next Year-5.03%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-10.8%
EBIT growth 1Y-30.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.36%
OCF growth 3YN/A
OCF growth 5YN/A